The commercial genetic testing landscape for Parkinson's disease

Lola Cook (Lead / Corresponding author), Jeanine Schulze, Jennifer Verbrugge, James C. Beck, Karen S. Marder, Rachel Saunders-Pullman, Christine Klein, Anna Naito, Roy N. Alcalay, ,

Research output: Contribution to journalArticlepeer-review

13 Citations (Scopus)
99 Downloads (Pure)


Introduction: There have been no specific guidelines regarding which genes should be tested in the clinical setting for Parkinson's disease (PD) or parkinsonism. We evaluated the types of clinical genetic testing offered for PD as the first step of our gene curation.

Methods: The National Institutes of Health (NIH) Genetic Testing Registry (GTR) was queried on 12/7/2020 to identify current commercial PD genetic test offerings by clinical laboratories, internationally.

Results: We identified 502 unique clinical genetic tests for PD, from 28 Clinical Laboratory Improvement Amendments (CLIA)-approved clinical laboratories. These included 11 diagnostic PD panels. The panels were notable for their differences in size, ranging from 5 to 62 genes. Five genes for variant query were included in all panels (SNCA, PRKN, PINK-1, PARK7 (DJ1), and LRRK2). Notably, the addition of the VPS35 and GBA genes was variable. Panel size differences stemmed from inclusion of genes linked to atypical parkinsonism and dystonia disorders, and genes in which the link to PD causation is controversial.

Conclusion: There is an urgent need for expert opinion regarding which genes should be included in a commercial laboratory multi-gene panel for PD.

Original languageEnglish
Pages (from-to)107-111
Number of pages5
JournalParkinsonism & Related Disorders
Early online date19 Oct 2021
Publication statusPublished - Nov 2021


  • Parkinson's disease
  • Genetic testing
  • Clinical laboratories
  • Multi-gene panels


Dive into the research topics of 'The commercial genetic testing landscape for Parkinson's disease'. Together they form a unique fingerprint.

Cite this